The RECOVERY trial is a large, ongoing, multi-centre, open-label, randomized controlled trial investigating several treatments for patients hospitalized with COVID-19. In July 2020, the preliminary results were published comparing dexamethasone plus usual standard of care with usual standard of care alone. Dexamethasone reduced the 28-day mortality rate in patients hospitalized with COVID-19. The purpose of this CADTH report is to describe the internal and external validity of these published results of the RECOVERY trial.

Link to Report

Dexamethasone in the Treatment of Hospitalized Patients With COVID-19: A Critical Appraisal of the RECOVERY Study

Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.